Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunology
Open single-cell discovery grant for oncology and immunology up to 100K Euro aimed at addressing unmet clinical needs.
Immunological diseases and Cancer are complex disorders and pose an enormous clinical burden due to diagnosis, stratification, and treatment challenges. Single-cell technologies are powerful in analysing the cellular landscape within complex diseases and are increasingly popular as a tool in identifying rare cells underlying the etiology of disease onset and progression in these areas. We are opening a single-cell discovery grant for oncology and immunology.
Scailyte is a recognized leader in combining single-cell analysis with artificial intelligence (AI) based data analytics. Our best-in-class algorithm associates patterns in single-cell data with disease status and further integrates multiple clinical parameters for a sensitive and impactful discovery.
We offer a co-finance partnership sharing 50% of costs (up to 100K Euro) for single-cell data acquisition including scRNA sequencing and CyTOF analysis, and subsequent artificial intelligence (AI)-based high-end bioinformatics services for translational oncology and immunology projects. The expected outcome of these grants should be addressing unmet medical needs and targets the discovery of clinically relevant biosignatures from single-cell data for diagnostic and prognostic pharmaceutical use. A maximum of three projects will be selected for this award through a formal selection process and notified within one month of the deadline.
Application:
Link to the brief application form: Click Here
Deadline: 30th September 2021
Recent News
Scailyte closes Series A funding with a CHF 6 million investment
Scailyte has successfully finished the Series A funding raising CHF 6 million from a Swiss family of
Recent News
VACANCY: Internship in Women’s Health R&D
The internship in Women’s Health R&D will focus on our in vitro diagnostics development work in en
Recent News
Nilogen and Scailyte Are Joining Forces to Find the “Right” Treatment for Every Patient
Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and t
Recent News
Machine learning meets multi-omics for precision medicine
Bringing industry and academia together to discuss the potential impact of single-cell analytics pow
Recent News
Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies
Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better
Recent News
VACANCY: Technical Lead / Product Owner for a clinical diagnostic software
Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cel
Recent News
VACANCY: Data Scientist in Biomarker Discovery
Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cel
Recent News
True precision medicine through single-cell science - Nature
ScaiVision identifies disease signatures predicting drug efficacy & drug mode of action. Precision m
Recent News
Scailyte closes Series A funding with a CHF 6 million investment
Scailyte has successfully finished the Series A funding raising CHF 6 million from a Swiss family of
VACANCY: Internship in Women’s Health R&D
The internship in Women’s Health R&D will focus on our in vitro diagnostics development work in en
Recent News
Nilogen and Scailyte Are Joining Forces to Find the “Right” Treatment for Every Patient
Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and t
Machine learning meets multi-omics for precision medicine
Bringing industry and academia together to discuss the potential impact of single-cell analytics pow
Recent News
Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies
Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better
VACANCY: Technical Lead / Product Owner for a clinical diagnostic software
Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cel
Recent News
VACANCY: Data Scientist in Biomarker Discovery
Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cel
True precision medicine through single-cell science - Nature
ScaiVision identifies disease signatures predicting drug efficacy & drug mode of action. Precision m